NAMPT Protein, Human (His)

NAMPT protein catalyzes the synthesis of nicotinamide mononucleotide, a key intermediate in NAD biosynthesis. NAMPT Protein, Human (His) is the recombinant human-derived NAMPT protein, expressed by E. coli , with N-6*His labeled tag.

NAMPT serves as the catalyst for the condensation reaction between nicotinamide and 5-phosphoribosyl-1-pyrophosphate, giving rise to nicotinamide mononucleotide—a pivotal intermediate in the biosynthesis of NAD. As the rate-limiting factor in the mammalian NAD biosynthetic pathway, NAMPT holds a central role in cellular processes. Beyond its enzymatic function, the secreted form of NAMPT exhibits dual properties, acting as both a cytokine with immunomodulating effects and an adipokine with anti-diabetic attributes. Notably, its extracellular function lacks enzymatic activity, partially due to the absence of activation by ATP, which is present at low levels in the extracellular space and plasma. Moreover, NAMPT plays a crucial role in the modulation of circadian clock function, orchestrating the oscillatory production of NAD to regulate clock target gene expression by facilitating the release of the CLOCK-BMAL1 heterodimer from NAD-dependent SIRT1-mediated suppression.

1.Measured by its ability to convert PRPP to NMN. The specific activity is 15.13987 pmol/min/µg, as measured under the described conditions.
2.Measured by its ability to induce VEGF secretion by PC-3 human prostate cancer cells. The ED₅₀ for this effect is 0.5-2.0 μg/mL.

• 
  Measured by its ability to induce VEGF secretion by PC-3 human prostate cancer cells. The ED₅₀ for this effect is 0.7365 μg/mL, corresponding to a specific activity is 1.36×10³ U/mg.

Human

E. coli

N-6*His

P43490 (M1-H491)

10135  [NCBI]

Full Length

MNPAAEAEFNILLATDSYKVTHYKQYPPNTSKVYSYFECREKKTENSKLRKVKYEETVFYGLQYILNKYLKGKVVTKEKIQEAKDVYKEHFQDDVFNEKGWNYILEKYDGHLPIEIKAVPEGFVIPRGNVLFTVENTDPECYWLTNWIETILVQSWYPITVATNSREQKKILAKYLLETSGNLDGLEYKLHDFGYRGVSSQETAGIGASAHLVNFKGTDTVAGLALIKKYYGTKDPVPGYSVPAAEHSTITAWGKDHEKDAFEHIVTQFSSVPVSVVSDSYDIYNACEKIWGEDLRHLIVSRSTQAPLIIRPDSGNPLDTVLKVLEILGKKFPVTENSKGYKLLPPYLRVIQGDGVDINTLQEIVEGMKQKMWSIENIAFGSGGGLLQKLTRDLLNCSFKCSYVVTNGLGINVFKDPVADPNKRSKKGRLSLHRTPAGNFVTLEEGKGDLEEYGQDLLHTVFKNGKVTKSYSFDEIRKNAQLNIELEAAHH

Approximately 55-57 kDa

• 
  ≥ 90%, as determined by reducing SDS-PAGE.

Lyophilized powder

1.Lyophilized from a 0.22 μm filtered solution of 20 mM PB, 10% trehalose, 100 mM Arg-HCl, 0.02% Tween 80, pH 6.0.
2.Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4, 10% trehalose, 0.02% Tween 80.
3.Lyophilized from a 0.22 μm filtered solution of PBS, pH 8.0, 8% trehalose.
Please refer to the lot-specific COA for specific buffer information.

<1 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.